Drug news
Complete Response Letter from FDA for Levadex (MAP Pharma) for Migraine
The FDA has issued a Complete Response Letter to MAP Pharma to its new drug application for Levadex (dihydroergotamine meyslate) inhalation aerosol for the acute treatment of Migraine. The FDA has raised issues on chemistry, manufacturing and controls but has not required a new trial Allergan will co-market Levadex in the USA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins